Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Rhythm Pharmaceuticals (RYTM) Return on Sales (2021 - 2025)

Rhythm Pharmaceuticals (RYTM) has disclosed Return on Sales for 5 consecutive years, with 0.83% as the latest value for Q4 2025.

  • On a quarterly basis, Return on Sales rose 21.0% to 0.83% in Q4 2025 year-over-year; TTM through Dec 2025 was 1.04%, a 97.0% increase, with the full-year FY2025 number at 1.04%, up 97.0% from a year prior.
  • Return on Sales was 0.83% for Q4 2025 at Rhythm Pharmaceuticals, up from 1.03% in the prior quarter.
  • In the past five years, Return on Sales ranged from a high of 5.28% in Q4 2022 to a low of 1607.14% in Q1 2021.
  • A 5-year average of 94.06% and a median of 2.19% in 2023 define the central range for Return on Sales.
  • Peak YoY movement for Return on Sales: skyrocketed 157208bps in 2022, then plummeted -700bps in 2023.
  • Rhythm Pharmaceuticals' Return on Sales stood at 27.99% in 2021, then skyrocketed by 119bps to 5.28% in 2022, then plummeted by -133bps to 1.72% in 2023, then surged by 40bps to 1.03% in 2024, then rose by 20bps to 0.83% in 2025.
  • Per Business Quant, the three most recent readings for RYTM's Return on Sales are 0.83% (Q4 2025), 1.03% (Q3 2025), and 0.96% (Q2 2025).